Citations

Mayo Clinic

Showing 10 of 108522 citations.

Self‐rated and informant‐rated everyday function in comparison to objective markers of Alzheimer's disease
Rueda, Alicia D., Saito, Naomi , Harvey, Danielle , Risacher, Shannon L. , Aisen, Paul , Petersen, Ronald C. , Saykin, Andrew J. , Farias, Sarah Tomaszewski , Initiative, Alzheimer's Disease Neuroimaging, Lau, Karen M. , Initiative, Alzheimer's Disease Neuroimaging, Saykin, Andrew J , Harvey, Danielle J

Alzheimer's & Dementia | November 17, 2014 | Volume: 11 | Issue: 9 | Pages: 1080-1089

10.1016/j.jalz.2014.09.002 | PMID 25449531 Get It

It is recognized that individuals with mild cognitive impairment (MCI) already demonstrate difficulty in aspects of daily functioning, which predicts disease progression. This study examined the relationship between self‐ versus informant‐report of functional ability, and how those reports relate to objective disease measures across the disease spectrum (i.e. cognitively normal, MCI, Alzheimer's disease). A total of 1080 subjects with self‐ and/or informant‐rated Everyday Cognition questionnaires were included. Objective measures included cognitive functioning, structural brain atrophy, cerebrospinal fluid abnormalities, and a marker of amyloid deposition using positron emission tomography with [ 18 F]AV45 (florbetapir). Overall, informant‐report was consistently more associated with objective markers of disease than self‐report although self‐reported functional status may still have some utility in early disease.
Effects of Sex and Gender on Adaptations to Space: Reproductive Health
Ronca, April E. , Baker, Ellen , Bavendam, Tamara , Beck, Kevin D. , Miller, Virginia M. , Tash, Joseph S. , Jenkins, Marjorie

Journal of Women's Health | November 17, 2014 | Volume: 23 | Issue: 11 | Pages: 967-974

10.1089/jwh.2014.4915 | PMID 25401943 Get It

In this report, sex/gender research relevant to reproduction on Earth, in conjunction with the extant human and animal observations in space, was used to identify knowledge gaps and prioritize recommendations for future sex- and gender-specific surveillance and monitoring of male and female astronauts. With overall increased durations of contemporary space missions, a deeper understanding of sex/gender effects on reproduction-related responses and adaptations to the space environment is warranted to minimize risks and insure healthy aging of the men and women who travel into space.
Stem Cells: The Pursuit of Genomic Stability
Wyles, Saranya P. , Brandt, Emma B. , Nelson, Timothy J.

International Journal of Molecular Sciences | November 17, 2014 | Volume: 15 | Issue: 11 | Pages: 20948-20967

10.3390/ijms151120948 | PMID 25405730 Get It

Stem cells harbor significant potential for regenerative medicine as well as basic and clinical translational research. Prior to harnessing their reparative nature for degenerative diseases, concerns regarding their genetic integrity and mutation acquisition need to be addressed. Here we review pluripotent and multipotent stem cell response to DNA damage including differences in DNA repair kinetics, specific repair pathways (homologous recombination vs. non-homologous end joining), and apoptotic sensitivity. We also describe DNA damage and repair strategies during reprogramming and discuss potential genotoxic agents that can reduce the inherent risk for teratoma formation and mutation accumulation. Ensuring genomic stability in stem cell lines is required to achieve the quality control standards for safe clinical application.
Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database
Sourbeer, Katharine N., Howard, Lauren E. , Moreira, Daniel M. , Amarasekara, Hiruni S., Chow, Lydia D., Cockrell, Dillon C. , Hanyok, Brian T. , Pratson, Connor L., Terris, Martha K. , Amling, Christopher L. , Hernandez, Rohini K. , Freedland, Stephen J. , Kane, Christopher J. , Aronson, William J. , Cooperberg, Matthew R , Howard, Lauren E

Journal of Urology | November 17, 2014 | Volume: 193 | Issue: 4 | Pages: 1232-1238

10.1016/j.juro.2014.11.014 | PMID 25463986 Get It

Hyperoxia-induced changes in estradiol metabolism in postnatal airway smooth muscle
Martin, Yvette N. , Manlove, L., Dong, Jie , Carey, William A., Pandya, Hitesh , Martin, Richard J. , Wigle, Dennis A. , Prakash, Y. S. , Manlove, Logan, Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y S

American Journal of Physiology-Lung Cellular and Molecular Physiology | November 15, 2014 | Volume: 308 | Issue: 2 | Pages: L141-L146

10.1152/ajplung.00266.2014 | PMID 25399436 Get It

Supplemental oxygen, used to treat hypoxia in preterm and term neonates, increases the risk of neonatal lung diseases, such as bronchopulmonary dysplasia (BPD) and asthma. There is a known sex predilection for BPD, but the underlying mechanisms are not clear. We tested the hypothesis that altered, local estradiol following hyperoxia contributes to pathophysiological changes observed in immature lung. In human fetal airway smooth muscle (fASM) cells exposed to normoxia or hyperoxia, we measured the expression of proteins involved in estrogen metabolism and cell proliferation responses to estradiol. In fASM cells, CYP1a1 expression was increased by hyperoxia, whereas hyperoxia-induced enhancement of cell proliferation was blunted by estradiol. Pharmacological studies indicated that these effects were attributable to upregulation of CYP1a1 and subsequent increased metabolism of estradiol to a downstream intermediate 2-methoxyestradiol. Microarray analysis of mouse lung exposed to 14 days of hyperoxia showed the most significant alteration in CYP1a1 expression, with minimal changes in expression of five other genes related to estrogen receptors, synthesis, and metabolism. Our novel results on estradiol metabolism in fetal and early postnatal lung in the context of hyperoxia indicate CYP1a1 as a potential mechanism for the protective effect of estradiol in hyperoxia-exposed immature lung, which may help explain the sex difference in neonatal lung diseases.
Chemoreflex physiology and implications for sleep apnoea: insights from studies in humans
Mansukhani, Meghna P. , Wang, Shihan , Somers, Virend K. , Mansukhani, Meghna P

Experimental Physiology | November 15, 2014 | Volume: 100 | Issue: 2 | Pages: 130-135

10.1113/expphysiol.2014.082826 | PMID 25398715 Get It

New Findings What is the topic of this review? This review summarizes chemoreflex physiology in health and disease, with specific focus on chemoreflex‐mediated pathophysiology in obstructive and central sleep apnoea. What advances does it highlight? Chemoreflex mechanisms are thought to contribute significantly to the pathophysiology and adverse outcomes seen in sleep apnoea. Clinical implications of altered chemoreflex function in sleep apnoea from recent studies in humans, including cardiac arrhythmias, coronary artery disease, systolic/diastolic heart failure and sudden cardiac death are highlighted. Activation of the chemoreflex in response to hypoxaemia results in an increase in sympathetic neural outflow. This process is predominantly mediated by the peripheral chemoreceptors in the carotid bodies and is potentiated by the absence of the sympatho‐inhibitory influence of ventilation during apnoea, as is seen in patients with sleep apnoea. In these patients, repetitive nocturnal hypoxaemia and apnoea elicit sympathetic activation, which may persist into wakefulness and is thought to contribute to the development of systemic hypertension and cardiac and vascular dysfunction. Chemoreflex activation could possibly lead to adverse cardiovascular outcomes, such as nocturnal myocardial infarction, systolic and/or diastolic heart failure, cardiac arrhythmias and sudden death in patients with sleep apnoea. This review summarizes chemoreflex physiology in health and disease, with specific focus on chemoreflex‐mediated pathophysiology in obstructive and central sleep apnoea. Measurement of the chemoreflex response may serve as a potential avenue for individualized screening for cardiovascular disease. Whether modulation of this response in sleep apnoea may aid in the prevention and treatment of adverse cardiovascular consequences will require further study.
Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer
Atherton, Pamela J. , Maurer, Matthew J. , Knutson, Keith L. , Dowdy, Sean C. , Cliby, William A. , Haluska, Paul , Long, Harry J., Oberg, Ann L. , Aderca, Ileana, Block, Matthew S. , Federspiel, Mark J. , Russell, Stephen J. , Kalli, Kimberly R., Keeney, Gary, Peng, Kah Whye, Hartmann, Lynn C. , Galanis, Evanthia , Öberg, Ann, Bakkum-Gamez, Jamie, Knutson, Keith L. , Bakkum‐Gamez, Jamie N. , Maurer, Matthew , Russell, Stephen J

Cancer Research | November 15, 2014 | Volume: 75 | Issue: 1 | Pages: 22-30

10.1158/0008-5472.can-14-2533 | PMID 25398436 Get It

Abstract Edmonston vaccine strains of measles virus (MV) have significant antitumor activity in mouse xenograft models of ovarian cancer. MV engineered to express the sodium iodide symporter gene (MV-NIS) facilitates localization of viral gene expression and offers a tool for tumor radiovirotherapy. Here, we report results from a clinical evaluation of MV-NIS in patients with taxol- and platinum-resistant ovarian cancer. MV-NIS was given intraperitoneally every 4 weeks for up to 6 cycles. Treatment was well tolerated and associated with promising median overall survival in these patients with heavily pretreated ovarian cancer; no dose-limiting toxicity was observed in 16 patients treated at high-dose levels (108–109 TCID50), and their median overall survival of 26.5 months compared favorably with other contemporary series. MV receptor CD46 and nectin-4 expression was confirmed by immunohistochemistry in patient tumors. Sodium iodide symporter expression in patient tumors after treatment was confirmed in three patients by 123I uptake on SPECT/CTs and was associated with long progression-free survival. Immune monitoring posttreatment showed an increase in effector T cells recognizing the tumor antigens IGFBP2 and FRα, indicating that MV-NIS treatment triggered cellular immunity against the patients' tumor and suggesting that an immune mechanism mediating the observed antitumor effect. Our findings support further clinical evaluation of MV-NIS as an effective immunovirotherapy. Cancer Res; 75(1); 22–30. ©2014 AACR.
Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?
Snyder, Peter J. , Kahle‐Wrobleski, Kristin, Brannan, Stephen K. , Schindler, Rachel, DeSanti, Susan, Ryan, J. Michael, Morrison, G. , Grundman, Michael, Chandler, Julie , Caselli, Richard J. , Isaac, Maria , Bain, Lisa J. , Carrillo, María C. , Miller, David S.

Alzheimer's & Dementia | November 15, 2014 | Volume: 10 | Issue: 6 | Pages: 853-860

10.1016/j.jalz.2014.07.158 | PMID 25458309 Get It

AbstractSeveral lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The National Institute on Aging—Alzheimer's Association revised criteria for AD provided a framework for this new thinking. As a result of this growing understanding, several research efforts have launched or will be launching large secondary prevention trials in AD. These and other efforts have clearly demonstrated a need for better measures of cognitive and functional change in people with the earliest changes associated with AD. Recent draft guidance from the US Food and Drug Administration further elevated the importance of cognitive and functional assessments in early stage clinical trials by proposing that even in the pre‐symptomatic stages of the disease, approval will be contingent on demonstrating clinical meaningfulness. The Alzheimer's Association's Research Roundtable addressed these issues at its fall meeting October 28–29, 2013, in Washington, D.C. The focus of the discussion included the need for improved cognitive and functional outcome measures for clinical of participants with preclinical AD and those diagnosed with Mild Cognitive Impairment due to AD.